# Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia

> **NCT00328198** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 86 (actual)

## Conditions studied

- B-Cell Chronic Lymphocytic Leukemia (B-CLL)

## Interventions

- **BIOLOGICAL:** Alemtuzumab
- **BIOLOGICAL:** Alemtuzumab

## Key facts

- **NCT ID:** NCT00328198
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2014-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00328198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00328198, "Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00328198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*